Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ARDELYX, INC.

Get SEC filing alerts via email and in your feed for ARDELYX, INC.

ARDX

ARDELYX, INC.

About ARDELYX, INC.

Ardelyx, Inc. is a biopharmaceutical company dedicated to developing innovative, first-in-class therapies for unmet medical needs. Its key products, IBSRELA and XPHOZAH, target irritable bowel syndrome with constipation and chronic kidney disease, respectively. With a focus on minimizing side effects, Ardelyx aims to capture significant market opportunities in these areas. The company is expanding its commercial strategies and partnerships to enhance product accessibility and growth.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from ARDELYX, INC.

1
1
ARDELYX, INC. Ardelyx Reports $94.5 Million Revenue in Q1 2026, Driven by 38% Increase in Product Sales

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
ARDELYX, INC. Ardelyx Reports $407.3 Million Revenue for Fiscal Year 2025, Driven by IBSRELA Sales

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
ARDELYX, INC. Ardelyx Reports 12% Revenue Growth to $110.3 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
ARDELYX, INC. Ardelyx Reports 33% Revenue Growth to $97.7 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ARDELYX, INC. Ardelyx Reports 61% Revenue Growth to $74.1 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ARDELYX, INC. Ardelyx Reports $319.2 Million in Product Sales for 2024, Driven by IBSRELA and XPHOZAH

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
ARDELYX, INC. Ardelyx Reports 74% Revenue Growth, Net Loss in Q3 2024 Amid Rising Operating Expenses

Via official filing (AI summary) | over 1 year ago | 0 comments